Company intelligence / Profile preview

Replidyne, Inc.

Louisville, Colorado, United Statesbiospace.com ↗

Ownership: Private
Employees: ~5000
Development stage: Phase 1

Overview

Replidyne developed novel anti-infective drugs targeting bacterial DNA replication. Its lead program included faropenem medoxomil for adult and pediatric use. The company had clinical-stage assets with an NDA accepted by the FDA before its acquisition. No recent independent clinical results post-acquisition are available[5][6][7].

Therapeutic areas: Infectious Diseases
Modalities: Small molecules (antibiotics/anti-infectives)
Industry: Biotech

Drug pipeline

2 assets

bederocin

Unknown

1 more asset in the full pipeline.

Request access →

Partnerships

Forest Laboratories (collaboration on FDA filing for antibiotics)[5]

Beyond the preview

Go deeper on Replidyne, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Replidyne, Inc..

Explore the full profile